The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Open accessAbstract
Purpose: We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain metastasis. Patients and Methods: A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identified from six institutions; 84 of 90 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]), and 86 of 90 received tyrosine kinase inhibitor (TKI) therapy. Estimates for overall (OS) and intracranial progression-free survival were determined and clinical prognostic factors were identified by Cox proportional hazards modeling. Results: Median OS after development of brain metastases was 49.5 months (95% CI, 29.0 months to not reached), and median intracranial progression-free survival was 11.9 months (95% CI, 10.1 to 18.2 months). Forty-five percent of patients with follow-up had progressive brain metastases at death, and repeated interventions for brain metastases were common. Absence of extracranial metastases, Karnofsky performance score ≥ 90, and no history of TKIs before development of brain metastases were associated with improved survival (P = .003, < .001, and < .001, respectively), whereas a single brain metastasis or initial treatment with SRS versus WBRT were not (P = .633 and .666, respectively). Prognostic factors significant by multivariable analysis were used to describe four patient groups with 2-year OS estimates of 33%, 59%, 76%, and 100%, respectively (P < .001). Conclusion: Patients with brain metastases from ALK-rearranged NSCLC treated with radiotherapy (SRS and/or WBRT) and TKIs have prolonged survival, suggesting that interventions to control intracranial disease are critical. The refinement of prognosis for this molecular subtype of NSCLC identifies a population of patients likely to benefit from first-line SRS, close CNS observation, and treatment of emergent CNS disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425 · cited 2×
“8 months.(6,7) In comparison, we found that median survival in patients with tumors harboring an ALK rearrangement was 49.”
BackgroundSelf-citationCamidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Self-citationSperduto, P. W., Berkey, B., Gaspar, L. E., Mehta, M., & Curran, W. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.074 · Cited by 1,031
Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., Bhatt, A., Jensen, A. W., Brown, P. D., Shih, H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.025 · Cited by 985
Self-citationGadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · cited 2×
“Control of metastatic disease to the brain is now emerging as a crucial issue in the treatment of these patients, and it has been suggested that local control of disease at sites of oligoprogression may improve outcomes.(14,17) Local treatment strategies for brain metastases include whole-brain radiotherapy (WBRT), st…”
BackgroundSelf-citationSoffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636
Costa, D. B., Shaw, A. T., Ou, S.-H. I., Solomon, B. J., Riely, G. J., Ahn, M.-J., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 599
Self-citationCSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
Gaspar, L. E., Scott, C., Murray, K., & Curran, W. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00547-2 · Cited by 529
Sahgal, A., Aoyama, H., Kocher, M., Neupane, B., Collette, S., Tago, M., Shaw, P., Beyene, J., & Chang, E. L. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.10.024 · Cited by 420
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
Sørensen, J. B., Hansen, H. H., Hansen, M., & Dombernowsky, P. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1474 · Cited by 339
Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., & Camidge, D. R. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.010 · Cited by 221
Self-citationOu, S.-H. I., Jänne, P. A., Bartlett, C. H., Tang, Y., Kim, D.-W., Otterson, G. A., Crinò, L., Selaru, P., Cohen, D. P., Clark, J. W., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt572 · Cited by 219
Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., Chi, A. S., & Shaw, A. T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000455 · Cited by 168
Sperduto, C. M., Watanabe, Y., Mullan, J. C., Hood, T. W., Dyste, G. N., Watts, C. R., Bender, G. P., & Sperduto, P. W. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/109/12/s14 · Cited by 142
Chun, S. G., Choe, K. S., Iyengar, P., Yordy, J. S., & Timmerman, R. D. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22255 · Cited by 99
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer
Johung, K. L., Yao, X., Li, F., Yu, J. B., Gettinger, S. N., Goldberg, S. B., Decker, R. H., Hess, J. A., Chiang, V., & Contessa, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0836 · Cited by 95
Self-citation
Cited by
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Self-citationEttinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Self-citationNCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, D. S., Wood, D. E., Aggarwal, C., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0059 · Cited by 956
Sperduto, P. W., Yang, T. J., Beal, K., Pan, H., Brown, P. D., Bangdiwala, A., Shanley, R., Yeh, N., Gaspar, L. E., Braunstein, S., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3834 · Cited by 659
Self-citationSoffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Metadata
- Authors
- Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A., Lovly, C. M., Goldberg, S., Beal, K., Yu, J. B., Kavanagh, B. D., Chiang, V. L., Camidge, D. R., & Contessa, J. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-01-10
- Volume
- 34
- Issue
- 2
- Pages
- 123-129
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116478428
- Cited by
- 328
- References
- 29
- FWCI
- 28.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.